Imaging Discordance Drives Treatment Change Despite Limited Association with Progression After Lutetium-Based Radioligand Therapy (EANM 2026) - Sep 29, 2026 - Abstract #EP-1003; "Aim/Introduction: Radioligand therapy (RLT) with Lutetium-177 PSMA and Lutetium-177 DOTATATE is a key component of theranostic oncology... FDG-based mismatch is frequently interpreted as a marker of treatment failure, yet in this cohort it showed limited correlation with actual progression. Despite this weak association, mismatch appeared to strongly influence treatment decisions, often prompting early therapy switch. These findings suggest that imaging discordance may lead to premature treatment modification in theranostic practice."
Discordant
|
|
N. Kataev; E. Gromova; N. Grigorev; N. Berezina; K. Suprun
|